Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-01-28

AUTHORS

Ann M. McNeill, Glenn Davies, Eliza Kruger, Stacey Kowal, Tim Reason, Flavia Ejzykowicz, Hakima Hannachi, Nilo Cater, Euan McLeod

ABSTRACT

INTRODUCTION: Ertugliflozin is a new sodium-glucose co-transporter-2 inhibitor (SGLT2i) for the treatment of type 2 diabetes mellitus. As there are no head-to-head trials comparing the efficacy of SGLT2is, the primary objective of this analysis was to indirectly compare ertugliflozin to other SGLT2i in patient populations with inadequately controlled glycated hemoglobin (HbA1c > 7.0%) and previously treated with either diet/exercise, metformin alone or metformin plus a dipeptidyl peptidase-4 inhibitor (DPP4i). METHODS: A systematic literature review (SLR) identified randomized controlled trials (RCTs) reporting outcomes at 24-26 weeks of treatment. Comparators to ertugliflozin were the SGLT2is canagliflozin, dapagliflozin and empagliflozin, with non-SGLT2i comparators also evaluated third-line [insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs)]. Outcomes were change from baseline in HbA1c, weight and systolic blood pressure (SBP) as well as HbA1c < 7% and key safety events. Bayesian network meta-analysis was used to synthesize evidence. Results are presented as the median of the mean difference (MD) or as odds ratios with 95% credible intervals (CrI). RESULTS: In patients uncontrolled on diet/exercise, the efficacy of ertugliflozin 5 mg monotherapy was not significantly different from that of other low-dose SGLT2is in terms of HbA1c reduction, while ertugliflozin 15 mg was more effective than dapagliflozin 10 mg (MD - 0.36%, CrI - 0.65, - 0.08) and empagliflozin 25 mg (MD - 0.31%, CrI - 0.58, - 0.04). As add-on therapy to metformin, ertugliflozin 5 mg was more effective in lowering HbA1c than dapagliflozin 5 mg (MD - 0.22%, CrI - 0.42, - 0.02), and ertugliflozin 15 mg was more effective than dapagliflozin 10 mg (MD - 0.26%, CrI - 0.46, - 0.06) and empagliflozin 25 mg (MD - 0.23%, CrI - 0.44, - 0.03). Among patients uncontrolled on combination therapy metformin plus a DPP4i, no relevant RCTs with insulin were identified from the SLR. One study with a GLP-1 RA was included in a sensitivity analysis due to limited data. There were no differences between ertugliflozin 5 or 15 mg and other SGLT2is, with the exception of dapagliflozin 10 mg, which was significantly less effective when added to sitagliptin and metformin. Overall, there were no other significant differences for remaining efficacy and safety outcomes except for a lower SBP for canagliflozin 300 mg compared to ertugliflozin 15 mg in the diet/exercise population. CONCLUSIONS: Indirect comparisons for HbA1c reduction found that ertugliflozin 5 mg was more effective than dapagliflozin 5 mg when added to metformin monotherapy, whereas ertugliflozin 15 mg was more effective than dapagliflozin 10 mg and empagliflozin 25 mg when added to diet/exercise and to metformin monotherapy. The HbA1c reduction associated with ertugliflozin was no different than that associated with canagliflozin across all populations. FUNDING: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Pfizer Inc., New York, NY, USA. More... »

PAGES

473-491

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-019-0566-x

DOI

http://dx.doi.org/10.1007/s13300-019-0566-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111682508

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30689140


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Merck & Co., Inc., Kenilworth, NJ USA", 
          "id": "http://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Merck & Co., Inc., Kenilworth, NJ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McNeill", 
        "givenName": "Ann M.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck & Co., Inc., Kenilworth, NJ USA", 
          "id": "http://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Merck & Co., Inc., Kenilworth, NJ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davies", 
        "givenName": "Glenn", 
        "id": "sg:person.0710401212.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710401212.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "IQVIA, Parsippany, NJ USA", 
          "id": "http://www.grid.ac/institutes/grid.418848.9", 
          "name": [
            "IQVIA, Parsippany, NJ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kruger", 
        "givenName": "Eliza", 
        "id": "sg:person.011122037536.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011122037536.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "IQVIA, Parsippany, NJ USA", 
          "id": "http://www.grid.ac/institutes/grid.418848.9", 
          "name": [
            "IQVIA, Parsippany, NJ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kowal", 
        "givenName": "Stacey", 
        "id": "sg:person.01300202725.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300202725.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "IQVIA, Parsippany, NJ USA", 
          "id": "http://www.grid.ac/institutes/grid.418848.9", 
          "name": [
            "IQVIA, Parsippany, NJ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reason", 
        "givenName": "Tim", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck & Co., Inc., Kenilworth, NJ USA", 
          "id": "http://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Merck & Co., Inc., Kenilworth, NJ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ejzykowicz", 
        "givenName": "Flavia", 
        "id": "sg:person.01077163317.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077163317.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck & Co., Inc., Kenilworth, NJ USA", 
          "id": "http://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Merck & Co., Inc., Kenilworth, NJ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hannachi", 
        "givenName": "Hakima", 
        "id": "sg:person.01101301445.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101301445.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, New York, NY USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer, New York, NY USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cater", 
        "givenName": "Nilo", 
        "id": "sg:person.01347267522.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347267522.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, Tadworth, UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer, Tadworth, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McLeod", 
        "givenName": "Euan", 
        "id": "sg:person.01337061043.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337061043.47"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s13300-017-0354-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100078266", 
          "https://doi.org/10.1007/s13300-017-0354-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-014-0337-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023128445", 
          "https://doi.org/10.1007/s40265-014-0337-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1741-7015-12-93", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036633908", 
          "https://doi.org/10.1186/1741-7015-12-93"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1008929526011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031552564", 
          "https://doi.org/10.1023/a:1008929526011"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-013-3039-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016452155", 
          "https://doi.org/10.1007/s00125-013-3039-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-018-0482-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106225069", 
          "https://doi.org/10.1007/s13300-018-0482-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-01-28", 
    "datePublishedReg": "2019-01-28", 
    "description": "INTRODUCTION: Ertugliflozin is a new sodium-glucose co-transporter-2 inhibitor (SGLT2i) for the treatment of type 2 diabetes mellitus. As there are no head-to-head trials comparing the efficacy of SGLT2is, the primary objective of this analysis was to indirectly compare ertugliflozin to other SGLT2i in patient populations with inadequately controlled glycated hemoglobin (HbA1c\u2009>\u20097.0%) and previously treated with either diet/exercise, metformin alone or metformin plus a dipeptidyl peptidase-4 inhibitor (DPP4i).\nMETHODS: A systematic literature review (SLR) identified randomized controlled trials (RCTs) reporting outcomes at 24-26\u00a0weeks of treatment. Comparators to ertugliflozin were the SGLT2is canagliflozin, dapagliflozin and empagliflozin, with non-SGLT2i comparators also evaluated third-line [insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs)]. Outcomes were change from baseline in HbA1c, weight and systolic blood pressure (SBP) as well as HbA1c\u2009<\u20097% and key safety events. Bayesian network meta-analysis was used to synthesize evidence. Results are presented as the median of the mean difference (MD) or as odds ratios with 95% credible intervals (CrI).\nRESULTS: In patients uncontrolled on diet/exercise, the efficacy of ertugliflozin 5\u00a0mg monotherapy was not significantly different from that of other low-dose SGLT2is in terms of HbA1c reduction, while ertugliflozin 15\u00a0mg was more effective than dapagliflozin 10\u00a0mg (MD -\u20090.36%, CrI -\u20090.65, -\u20090.08) and empagliflozin 25\u00a0mg (MD -\u20090.31%, CrI -\u20090.58, -\u20090.04). As add-on therapy to metformin, ertugliflozin 5\u00a0mg was more effective in lowering HbA1c than dapagliflozin 5\u00a0mg (MD -\u20090.22%, CrI -\u20090.42, -\u20090.02), and ertugliflozin 15\u00a0mg was more effective than dapagliflozin 10\u00a0mg (MD -\u20090.26%, CrI -\u20090.46, -\u20090.06) and empagliflozin 25\u00a0mg (MD -\u20090.23%, CrI -\u20090.44, -\u20090.03). Among patients uncontrolled on combination therapy metformin plus a DPP4i, no relevant RCTs with insulin were identified from the SLR. One study with a GLP-1 RA was included in a sensitivity analysis due to limited data. There were no differences between ertugliflozin 5 or 15\u00a0mg and other SGLT2is, with the exception of dapagliflozin 10\u00a0mg, which was significantly less effective when added to sitagliptin and metformin. Overall, there were no other significant differences for remaining efficacy and safety outcomes except for a lower SBP for canagliflozin 300\u00a0mg compared to ertugliflozin 15\u00a0mg in the diet/exercise population.\nCONCLUSIONS: Indirect comparisons for HbA1c reduction found that ertugliflozin 5\u00a0mg was more effective than dapagliflozin 5\u00a0mg when added to metformin monotherapy, whereas ertugliflozin 15\u00a0mg was more effective than dapagliflozin 10\u00a0mg and empagliflozin 25\u00a0mg when added to diet/exercise and to metformin monotherapy. The HbA1c reduction associated with ertugliflozin was no different than that associated with canagliflozin across all populations.\nFUNDING: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Pfizer Inc., New York, NY, USA.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-019-0566-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "keywords": [
      "sodium-glucose co-transporter-2 inhibitors", 
      "dipeptidyl peptidase-4 inhibitors", 
      "systolic blood pressure", 
      "diet/exercise", 
      "dapagliflozin 10", 
      "ertugliflozin 15", 
      "dapagliflozin 5", 
      "ertugliflozin 5", 
      "lower systolic blood pressure", 
      "type 2 diabetes mellitus", 
      "systematic literature review", 
      "mean difference", 
      "trials (RCTs) reporting outcomes", 
      "GLP-1 RAs", 
      "peptidase-4 inhibitors", 
      "weeks of treatment", 
      "Network Meta-Analysis", 
      "anti-hyperglycemic agents", 
      "subsidiary of Merck", 
      "canagliflozin 300", 
      "metformin monotherapy", 
      "HbA1c reduction", 
      "head trials", 
      "relevant RCTs", 
      "diabetes mellitus", 
      "blood pressure", 
      "Dohme Corp.", 
      "patient population", 
      "glycated hemoglobin", 
      "odds ratio", 
      "safety outcomes", 
      "monotherapy", 
      "indirect comparison", 
      "metformin", 
      "type 2", 
      "Meta-Analysis", 
      "ertugliflozin", 
      "literature review", 
      "reporting outcomes", 
      "Merck Sharp", 
      "safety events", 
      "Pfizer Inc.", 
      "limited data", 
      "exercise population", 
      "efficacy", 
      "significant differences", 
      "canagliflozin", 
      "patients", 
      "therapy", 
      "outcomes", 
      "exercise", 
      "treatment", 
      "primary objective", 
      "inhibitors", 
      "population", 
      "mellitus", 
      "empagliflozin", 
      "review", 
      "dapagliflozin", 
      "RCTs", 
      "sitagliptin", 
      "differences", 
      "insulin", 
      "baseline", 
      "trials", 
      "weeks", 
      "hemoglobin", 
      "median", 
      "reduction", 
      "comparator", 
      "credible intervals", 
      "Merck", 
      "add", 
      "agents", 
      "head", 
      "RA", 
      "evidence", 
      "intervals", 
      "weight", 
      "study", 
      "sensitivity analysis", 
      "New York", 
      "events", 
      "analysis", 
      "NY", 
      "pressure", 
      "changes", 
      "objective", 
      "exception", 
      "USA", 
      "Sharp", 
      "data", 
      "ratio", 
      "comparison", 
      "Kenilworth", 
      "Inc.", 
      "results", 
      "York", 
      "terms", 
      "NJ", 
      "Bayesian network", 
      "Corp.", 
      "Co.", 
      "network", 
      "subsidiaries", 
      "new sodium-glucose co-transporter-2 inhibitor", 
      "co-transporter-2 inhibitor", 
      "efficacy of SGLT2is", 
      "non-SGLT2i comparators", 
      "key safety events", 
      "low-dose SGLT2is", 
      "combination therapy metformin", 
      "therapy metformin", 
      "diet/exercise population"
    ], 
    "name": "Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis", 
    "pagination": "473-491", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111682508"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-019-0566-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30689140"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-019-0566-x", 
      "https://app.dimensions.ai/details/publication/pub.1111682508"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_804.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-019-0566-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-0566-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-0566-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-0566-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-0566-x'


 

This table displays all metadata directly associated to this object as RDF triples.

263 TRIPLES      22 PREDICATES      146 URIs      132 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-019-0566-x schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Ne73c0f0cc76e441aa54bdf83f05b2b1c
4 schema:citation sg:pub.10.1007/s00125-013-3039-1
5 sg:pub.10.1007/s13300-017-0354-4
6 sg:pub.10.1007/s13300-018-0482-5
7 sg:pub.10.1007/s40265-014-0337-y
8 sg:pub.10.1023/a:1008929526011
9 sg:pub.10.1186/1741-7015-12-93
10 schema:datePublished 2019-01-28
11 schema:datePublishedReg 2019-01-28
12 schema:description INTRODUCTION: Ertugliflozin is a new sodium-glucose co-transporter-2 inhibitor (SGLT2i) for the treatment of type 2 diabetes mellitus. As there are no head-to-head trials comparing the efficacy of SGLT2is, the primary objective of this analysis was to indirectly compare ertugliflozin to other SGLT2i in patient populations with inadequately controlled glycated hemoglobin (HbA1c > 7.0%) and previously treated with either diet/exercise, metformin alone or metformin plus a dipeptidyl peptidase-4 inhibitor (DPP4i). METHODS: A systematic literature review (SLR) identified randomized controlled trials (RCTs) reporting outcomes at 24-26 weeks of treatment. Comparators to ertugliflozin were the SGLT2is canagliflozin, dapagliflozin and empagliflozin, with non-SGLT2i comparators also evaluated third-line [insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs)]. Outcomes were change from baseline in HbA1c, weight and systolic blood pressure (SBP) as well as HbA1c < 7% and key safety events. Bayesian network meta-analysis was used to synthesize evidence. Results are presented as the median of the mean difference (MD) or as odds ratios with 95% credible intervals (CrI). RESULTS: In patients uncontrolled on diet/exercise, the efficacy of ertugliflozin 5 mg monotherapy was not significantly different from that of other low-dose SGLT2is in terms of HbA1c reduction, while ertugliflozin 15 mg was more effective than dapagliflozin 10 mg (MD - 0.36%, CrI - 0.65, - 0.08) and empagliflozin 25 mg (MD - 0.31%, CrI - 0.58, - 0.04). As add-on therapy to metformin, ertugliflozin 5 mg was more effective in lowering HbA1c than dapagliflozin 5 mg (MD - 0.22%, CrI - 0.42, - 0.02), and ertugliflozin 15 mg was more effective than dapagliflozin 10 mg (MD - 0.26%, CrI - 0.46, - 0.06) and empagliflozin 25 mg (MD - 0.23%, CrI - 0.44, - 0.03). Among patients uncontrolled on combination therapy metformin plus a DPP4i, no relevant RCTs with insulin were identified from the SLR. One study with a GLP-1 RA was included in a sensitivity analysis due to limited data. There were no differences between ertugliflozin 5 or 15 mg and other SGLT2is, with the exception of dapagliflozin 10 mg, which was significantly less effective when added to sitagliptin and metformin. Overall, there were no other significant differences for remaining efficacy and safety outcomes except for a lower SBP for canagliflozin 300 mg compared to ertugliflozin 15 mg in the diet/exercise population. CONCLUSIONS: Indirect comparisons for HbA1c reduction found that ertugliflozin 5 mg was more effective than dapagliflozin 5 mg when added to metformin monotherapy, whereas ertugliflozin 15 mg was more effective than dapagliflozin 10 mg and empagliflozin 25 mg when added to diet/exercise and to metformin monotherapy. The HbA1c reduction associated with ertugliflozin was no different than that associated with canagliflozin across all populations. FUNDING: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Pfizer Inc., New York, NY, USA.
13 schema:genre article
14 schema:inLanguage en
15 schema:isAccessibleForFree true
16 schema:isPartOf N0007626dfc1346f498329fa66a5f23a3
17 N679de89e802a45cbba7ac6b84a900201
18 sg:journal.1044057
19 schema:keywords Bayesian network
20 Co.
21 Corp.
22 Dohme Corp.
23 GLP-1 RAs
24 HbA1c reduction
25 Inc.
26 Kenilworth
27 Merck
28 Merck Sharp
29 Meta-Analysis
30 NJ
31 NY
32 Network Meta-Analysis
33 New York
34 Pfizer Inc.
35 RA
36 RCTs
37 Sharp
38 USA
39 York
40 add
41 agents
42 analysis
43 anti-hyperglycemic agents
44 baseline
45 blood pressure
46 canagliflozin
47 canagliflozin 300
48 changes
49 co-transporter-2 inhibitor
50 combination therapy metformin
51 comparator
52 comparison
53 credible intervals
54 dapagliflozin
55 dapagliflozin 10
56 dapagliflozin 5
57 data
58 diabetes mellitus
59 diet/exercise
60 diet/exercise population
61 differences
62 dipeptidyl peptidase-4 inhibitors
63 efficacy
64 efficacy of SGLT2is
65 empagliflozin
66 ertugliflozin
67 ertugliflozin 15
68 ertugliflozin 5
69 events
70 evidence
71 exception
72 exercise
73 exercise population
74 glycated hemoglobin
75 head
76 head trials
77 hemoglobin
78 indirect comparison
79 inhibitors
80 insulin
81 intervals
82 key safety events
83 limited data
84 literature review
85 low-dose SGLT2is
86 lower systolic blood pressure
87 mean difference
88 median
89 mellitus
90 metformin
91 metformin monotherapy
92 monotherapy
93 network
94 new sodium-glucose co-transporter-2 inhibitor
95 non-SGLT2i comparators
96 objective
97 odds ratio
98 outcomes
99 patient population
100 patients
101 peptidase-4 inhibitors
102 population
103 pressure
104 primary objective
105 ratio
106 reduction
107 relevant RCTs
108 reporting outcomes
109 results
110 review
111 safety events
112 safety outcomes
113 sensitivity analysis
114 significant differences
115 sitagliptin
116 sodium-glucose co-transporter-2 inhibitors
117 study
118 subsidiaries
119 subsidiary of Merck
120 systematic literature review
121 systolic blood pressure
122 terms
123 therapy
124 therapy metformin
125 treatment
126 trials
127 trials (RCTs) reporting outcomes
128 type 2
129 type 2 diabetes mellitus
130 weeks
131 weeks of treatment
132 weight
133 schema:name Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis
134 schema:pagination 473-491
135 schema:productId N2f9e7419d6fc47cfb8f7d1b6e2fb2790
136 N6809e26180db4fb88a0c51b03aa281f7
137 N81e5395dc02745fc8db2e9a3f7d1f00e
138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111682508
139 https://doi.org/10.1007/s13300-019-0566-x
140 schema:sdDatePublished 2022-01-01T18:52
141 schema:sdLicense https://scigraph.springernature.com/explorer/license/
142 schema:sdPublisher N89ba7f1e88674b7da890992752c3f39e
143 schema:url https://doi.org/10.1007/s13300-019-0566-x
144 sgo:license sg:explorer/license/
145 sgo:sdDataset articles
146 rdf:type schema:ScholarlyArticle
147 N0007626dfc1346f498329fa66a5f23a3 schema:volumeNumber 10
148 rdf:type schema:PublicationVolume
149 N0721cbf2890c4969be17b6ca31249f00 rdf:first sg:person.0710401212.06
150 rdf:rest N0750078d7b3a4872af0c73ae145a6009
151 N0750078d7b3a4872af0c73ae145a6009 rdf:first sg:person.011122037536.96
152 rdf:rest N61043cdde6c24df78a57a01ba460fbfd
153 N2dd9010be3fe4a58859fb9521dbeec73 rdf:first sg:person.01077163317.63
154 rdf:rest Nf2575a6fc1df4c7dafd9244eebcb7a3a
155 N2f9e7419d6fc47cfb8f7d1b6e2fb2790 schema:name pubmed_id
156 schema:value 30689140
157 rdf:type schema:PropertyValue
158 N556e4c2446cc41ef9c8c5ead825248ca schema:affiliation grid-institutes:grid.418848.9
159 schema:familyName Reason
160 schema:givenName Tim
161 rdf:type schema:Person
162 N61043cdde6c24df78a57a01ba460fbfd rdf:first sg:person.01300202725.74
163 rdf:rest Nb613cfb90f7b44ce8694414e9a538688
164 N64cb4de267f646f3ae511e4876d5f3c2 rdf:first sg:person.01347267522.97
165 rdf:rest Nd367f7591c1b416d87e7faf48c6a50aa
166 N679de89e802a45cbba7ac6b84a900201 schema:issueNumber 2
167 rdf:type schema:PublicationIssue
168 N6809e26180db4fb88a0c51b03aa281f7 schema:name doi
169 schema:value 10.1007/s13300-019-0566-x
170 rdf:type schema:PropertyValue
171 N81e5395dc02745fc8db2e9a3f7d1f00e schema:name dimensions_id
172 schema:value pub.1111682508
173 rdf:type schema:PropertyValue
174 N89ba7f1e88674b7da890992752c3f39e schema:name Springer Nature - SN SciGraph project
175 rdf:type schema:Organization
176 Nb613cfb90f7b44ce8694414e9a538688 rdf:first N556e4c2446cc41ef9c8c5ead825248ca
177 rdf:rest N2dd9010be3fe4a58859fb9521dbeec73
178 Nd367f7591c1b416d87e7faf48c6a50aa rdf:first sg:person.01337061043.47
179 rdf:rest rdf:nil
180 Ne73c0f0cc76e441aa54bdf83f05b2b1c rdf:first Neee3f19ff7ba49fe94b22e9350c9a6aa
181 rdf:rest N0721cbf2890c4969be17b6ca31249f00
182 Neee3f19ff7ba49fe94b22e9350c9a6aa schema:affiliation grid-institutes:grid.417993.1
183 schema:familyName McNeill
184 schema:givenName Ann M.
185 rdf:type schema:Person
186 Nf2575a6fc1df4c7dafd9244eebcb7a3a rdf:first sg:person.01101301445.58
187 rdf:rest N64cb4de267f646f3ae511e4876d5f3c2
188 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
189 schema:name Medical and Health Sciences
190 rdf:type schema:DefinedTerm
191 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
192 schema:name Clinical Sciences
193 rdf:type schema:DefinedTerm
194 sg:journal.1044057 schema:issn 1869-6953
195 1869-6961
196 schema:name Diabetes Therapy
197 schema:publisher Springer Nature
198 rdf:type schema:Periodical
199 sg:person.01077163317.63 schema:affiliation grid-institutes:grid.417993.1
200 schema:familyName Ejzykowicz
201 schema:givenName Flavia
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077163317.63
203 rdf:type schema:Person
204 sg:person.01101301445.58 schema:affiliation grid-institutes:grid.417993.1
205 schema:familyName Hannachi
206 schema:givenName Hakima
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101301445.58
208 rdf:type schema:Person
209 sg:person.011122037536.96 schema:affiliation grid-institutes:grid.418848.9
210 schema:familyName Kruger
211 schema:givenName Eliza
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011122037536.96
213 rdf:type schema:Person
214 sg:person.01300202725.74 schema:affiliation grid-institutes:grid.418848.9
215 schema:familyName Kowal
216 schema:givenName Stacey
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300202725.74
218 rdf:type schema:Person
219 sg:person.01337061043.47 schema:affiliation grid-institutes:grid.418566.8
220 schema:familyName McLeod
221 schema:givenName Euan
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337061043.47
223 rdf:type schema:Person
224 sg:person.01347267522.97 schema:affiliation grid-institutes:grid.410513.2
225 schema:familyName Cater
226 schema:givenName Nilo
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347267522.97
228 rdf:type schema:Person
229 sg:person.0710401212.06 schema:affiliation grid-institutes:grid.417993.1
230 schema:familyName Davies
231 schema:givenName Glenn
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710401212.06
233 rdf:type schema:Person
234 sg:pub.10.1007/s00125-013-3039-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016452155
235 https://doi.org/10.1007/s00125-013-3039-1
236 rdf:type schema:CreativeWork
237 sg:pub.10.1007/s13300-017-0354-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100078266
238 https://doi.org/10.1007/s13300-017-0354-4
239 rdf:type schema:CreativeWork
240 sg:pub.10.1007/s13300-018-0482-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106225069
241 https://doi.org/10.1007/s13300-018-0482-5
242 rdf:type schema:CreativeWork
243 sg:pub.10.1007/s40265-014-0337-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1023128445
244 https://doi.org/10.1007/s40265-014-0337-y
245 rdf:type schema:CreativeWork
246 sg:pub.10.1023/a:1008929526011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031552564
247 https://doi.org/10.1023/a:1008929526011
248 rdf:type schema:CreativeWork
249 sg:pub.10.1186/1741-7015-12-93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036633908
250 https://doi.org/10.1186/1741-7015-12-93
251 rdf:type schema:CreativeWork
252 grid-institutes:grid.410513.2 schema:alternateName Pfizer, New York, NY USA
253 schema:name Pfizer, New York, NY USA
254 rdf:type schema:Organization
255 grid-institutes:grid.417993.1 schema:alternateName Merck & Co., Inc., Kenilworth, NJ USA
256 schema:name Merck & Co., Inc., Kenilworth, NJ USA
257 rdf:type schema:Organization
258 grid-institutes:grid.418566.8 schema:alternateName Pfizer, Tadworth, UK
259 schema:name Pfizer, Tadworth, UK
260 rdf:type schema:Organization
261 grid-institutes:grid.418848.9 schema:alternateName IQVIA, Parsippany, NJ USA
262 schema:name IQVIA, Parsippany, NJ USA
263 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...